AVENUE THERAPEUTICS, INC. - Common Stock (ATXI)
CUSIP: 05360L403
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 3,190,732
- Total 13F shares
- 192,628
- Share change
- -4,896
- Total reported value
- $385,256
- Price per share
- $2.00
- Number of holders
- 7
- Value change
- -$102,432
- Number of buys
- 5
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 05360L403?
CUSIP 05360L403 identifies ATXI - AVENUE THERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 05360L403:
Top shareholders of ATXI - AVENUE THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
|
Company |
5%
from 13D/G
|
115,000
|
$286,350 | — | 30 Sep 2024 | |
| Robert L. Davidow |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,219,800
|
$170,772 | — | 11 Dec 2023 | |
| SABBY MANAGEMENT, LLC |
13F
|
Company |
2%
|
63,060
|
$157,019 | — | 30 Sep 2024 | |
| Lucy Lu |
3/4/5
|
President, CEO, Director |
—
class O/S missing
|
748,949
|
$104,853 | — | 17 Dec 2021 | |
| Moss Adams Wealth Advisors LLC |
13F
|
Company |
0.34%
|
11,000
|
$27,390 | — | 30 Sep 2024 | |
| Alexandra MacLean |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
170,000
|
$23,800 | — | 23 Sep 2024 | |
| Joseph Walter Vazzano |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
165,757
|
$23,206 | — | 17 Dec 2021 | |
| UBS Group AG |
13F
|
Company |
0.19%
|
6,143
|
$15,296 | — | 30 Sep 2024 | |
| David Jin |
3/4/5
|
Interim PFO and COO |
—
class O/S missing
|
65,000
|
$9,100 | — | 23 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.05%
|
1,740
|
$4,333 | — | 30 Sep 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
561
|
$1,397 | — | 30 Sep 2024 | |
| Jay D. Kranzler |
3/4/5
|
Director |
—
mixed-class rows
|
30,559
mixed-class rows
|
$1,252 | — | 05 Nov 2024 | |
| Neil Herskowitz |
3/4/5
|
Director |
—
mixed-class rows
|
30,097
mixed-class rows
|
$194 | — | 02 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
10
|
$25 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Sep 2024 | |
| Curtis Gale Oltmans |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 23 Sep 2024 | |
| Faith L. Charles |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 23 Sep 2024 | |
| Lindsay A. Rosenwald MD |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
— | — | 23 Sep 2024 |
Institutional Holders of AVENUE THERAPEUTICS, INC. - Common Stock (ATXI) as of Q4 2024
As of 31 Dec 2024,
AVENUE THERAPEUTICS, INC. - Common Stock (ATXI) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
192,628 shares.
The largest 7 holders included
Ikarian Capital, LLC, BOOTHBAY FUND MANAGEMENT, LLC, UBS Group AG, Tower Research Capital LLC (TRC), WELLS FARGO & COMPANY/MN, BANK OF AMERICA CORP /DE/, and SBI Securities Co., Ltd..
This page lists
7
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
8
Q4 2024 holders
7
Holder diff
-1
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.